NCT Number: NCT06954103
The incidence of stroke-heart syndrome following acute stroke, which encompasses both acute ischemic stroke and acute intracerebral hemorrhage, is notably high and is strongly associated with increased mortality and poor outcomes in stroke patients. However, the underlying mechanisms remain unclear, and there are currently no effective prevention or treatment strategies. This study aims to elucidate the neuro-humoral mechanisms of stroke-heart syndrome through multimodal imaging and multi-omics blood analysis. Additionally, it seeks to observe the progression of stroke-heart syndrome and its impact on functional outcomes, cognitive abilities, and emotional issues post-stroke. The research is expected to uncover novel blood biomarkers and brain network mechanisms associated with stroke-heart syndrome, providing potential targets and theoretical foundations for pharmacological treatments or physical interventions. Furthermore, it aims to establish a risk early-warning system for major cardiovascular complications post-stroke, enabling early identification, early intervention, and integrated brain-heart management to improve clinical outcomes for stroke patients.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Wuhan, Hubei, 430030, China
Location status: Recruiting
Bai
CONTACT
Chensheng Pan, MD
SUB_INVESTIGATOR
Guo Li, PhD
SUB_INVESTIGATOR
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: within 48 hours and at 72 hours after stroke onset
a marker of acute myocardial injury
Time frame: within 1 week after stroke onset
measured by transthoracic echocardiography; a marker of ventricular dysfunction and heart failure
Time frame: within 1 week after stroke onset
a marker of ventricular dysfunction and heart failure
Time frame: 3 months and 1 year after stroke onset.
measured by modified Rankin scale (mRS), a 7-level ordinal scale (scores 0-6) used to assess global disability after stroke. Higher scores indicate worse functional outcome.
Time frame: 1 month, 3 months and 1 year after stroke onset
Time frame: 3 months and 1 year after stroke onset.
measured by Montreal Cognitive Assessement (MoCA), a widely used screening tool designed to detect mild cognitive impairment and dementia. MoCA score range: 0-30, higher scores indicate better cognitive function.
Time frame: 3 months and 1 year after stroke onset.
measured by Hamilton depression rating scale (HAMD), a widely used clinician-administered tool for assessing the severity of depression. HAMD score range: 0-52. Higher scores indicate higher depression severity.
Time frame: 3 months and 1 year after stroke onset.
measured by Hamilton anxiety rating scale (HAMA), a clinician-administered tool to assess the severity of anxiety symptoms. HAMA score range: 0-56. Higher scores indicate higher anxiety severity.
Contact information is provided by the study sponsor or research team.
Chensheng Pan, M.D.
CONTACT
Zhou Zhu, MD, PhD
CONTACT
Chensheng Pan
Other
Acronym: MAP-SHS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07359872
Ablation of Atrial Fibrillation, Arrhythmia
View Trial DetailsNCT04096781
Arrhythmia, Arrhythmias, Cardiac
Palo Alto, California, United States
View Trial DetailsNCT02176174
Abdominal Aortic Aneurysm, Aneurysm
View Trial DetailsNCT06890208
Anxiety Disorders, Arrhythmias, Cardiac
Hamburg, Germany
View Trial Details